 In April, Kite has won the ‘Clinical Trial Result of the Year’ award for its CAR-T trial of Axicabtagene Ciloleucel in patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards.The award recognizes clinical achievements in the pharmaceutical industry and contribution to the advancement of therapies for unmet medical needs.In August, Kite has filed the first CAR-T candidate in Europe, seeking approval of its axicabtagene ciloleucel (KTE-C19) for two types of non-Hodgkin's lymphoma (NHL).